Shanghai Bio-heart Biological Technology Future Growth
Future criteria checks 2/6
Shanghai Bio-heart Biological Technology is forecast to grow earnings and revenue by 22.2% and 139.8% per annum respectively. EPS is expected to grow by 22.8% per annum. Return on equity is forecast to be -18.2% in 3 years.
Key information
22.2%
Earnings growth rate
22.8%
EPS growth rate
| Medical Equipment earnings growth | 33.7% |
| Revenue growth rate | 139.8% |
| Future return on equity | -18.2% |
| Analyst coverage | Low |
| Last updated | 23 Nov 2023 |
Recent future growth updates
No updates
Recent updates
Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth
Feb 22
Companies Like Shanghai Bio-heart Biological Technology (HKG:2185) Are In A Position To Invest In Growth
Nov 03We Think Shanghai Bio-heart Biological Technology (HKG:2185) Can Afford To Drive Business Growth
May 12We're Not Worried About Shanghai Bio-heart Biological Technology's (HKG:2185) Cash Burn
Sep 19Shanghai Bio-heart Biological Technology (HKG:2185) Is In A Good Position To Deliver On Growth Plans
Jun 03Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2025 | 293 | -123 | N/A | N/A | 1 |
| 12/31/2024 | 21 | -59 | N/A | N/A | 1 |
| 12/31/2023 | N/A | -176 | N/A | N/A | N/A |
| 9/30/2023 | N/A | -182 | N/A | N/A | N/A |
| 6/30/2023 | N/A | -189 | -167 | -144 | N/A |
| 3/31/2023 | N/A | -197 | -169 | -142 | N/A |
| 12/31/2022 | N/A | -204 | -171 | -141 | N/A |
| 9/30/2022 | N/A | -234 | -149 | -113 | N/A |
| 6/30/2022 | N/A | -263 | -128 | -85 | N/A |
| 3/31/2022 | N/A | -312 | -125 | -87 | N/A |
| 12/31/2021 | N/A | -361 | -123 | -88 | N/A |
| 9/30/2021 | N/A | -437 | -108 | -83 | N/A |
| 6/30/2021 | N/A | -512 | -93 | -78 | N/A |
| 3/31/2021 | N/A | -419 | -74 | -63 | N/A |
| 12/31/2020 | N/A | -326 | -54 | -48 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 2185 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 2185 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 2185 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 2185's revenue (139.8% per year) is forecast to grow faster than the Hong Kong market (8.2% per year).
High Growth Revenue: 2185's revenue (139.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 2185 is forecast to be unprofitable in 3 years.